USPTO Board Rules on PacBio, Life Tech Patent Interference Case
February 01, 2011
USPTO Board Rules on PacBio, Life Tech Patent Interference Case
The board has deemed all of Life Tech's involved claims and the broadest claims of both companies unpatentable, effectively ending the case unless Life Tech decides to appeal.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Launch of PacBio RS Drives Q2 Revenue, but Investors Raise Concerns Over Pace of Uptake
August 9, 2011 / In Sequence - PacBio Grows Order Backlog in Q4; Sees Increased Interest in Microbial Sequencing
February 22, 2011 / In Sequence - PacBio Reveals Beta System Specs for RS; Says Commercial Release is on Track for First Half of 2011
December 7, 2010 / In Sequence - PacBio Demos Improved Chemistry with E. coli Outbreak Sequencing; Plans Q4 Upgrade for RS
July 12, 2011 / In Sequence - PacBio Ships First Two Commercial Systems; Order Backlog Grows to 44
May 3, 2011 / In Sequence